Hot Features
Premium
Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Atea Pharmaceuticals Inc | AVIR | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.70 | 03:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.70 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.765 - 5.19 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 3.70 | USD |
Atea Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 311.41M | 84.16M | - | 0 | -135.96M | -1.62 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Atea Pharmaceuticals News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVIR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.82 | 3.89 | 3.68 | 3.73 | 206,205 | -0.12 | -3.14% |
| 1 Month | 4.10 | 4.135 | 3.68 | 3.86 | 248,004 | -0.40 | -9.76% |
| 3 Months | 3.80 | 4.60 | 3.68 | 4.08 | 407,538 | -0.10 | -2.63% |
| 6 Months | 2.93 | 4.60 | 2.765 | 3.56 | 428,548 | 0.77 | 26.28% |
| 1 Year | 3.23 | 5.19 | 2.765 | 3.71 | 480,091 | 0.47 | 14.55% |
| 3 Years | 44.97 | 46.9099 | 2.765 | 13.75 | 1,064,548 | -41.27 | -91.77% |
| 5 Years | 29.94 | 94.1737 | 2.765 | 15.58 | 973,457 | -26.24 | -87.64% |
Atea Pharmaceuticals Description
| Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science. |
